339 related articles for article (PubMed ID: 26068001)
41. Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response.
Pampena R; Benati E; Borsari S; Bombonato C; Lombardi M; Raucci M; Mirra M; Lallas A; Apalla Z; Papadimitriou I; Moscarella E; Kyrgidis A; Argenziano G; Pellacani G; Longo C
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1461-1468. PubMed ID: 29356164
[TBL] [Abstract][Full Text] [Related]
42. Field Treatment of Actinic Keratosis With Ingenol Mebutate.
Berman B; Stockfleth E
J Drugs Dermatol; 2016 May; 15(5):535-42. PubMed ID: 27168262
[TBL] [Abstract][Full Text] [Related]
43. Local skin reactions following the administration of topical ingenol mebutate for actinic keratosis.
Conde-Taboada A; Mercado B; Aranegui B; González-Guerra E; López-Bran E
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469731
[TBL] [Abstract][Full Text] [Related]
44. In vivo reflectance confocal microscopy characterization of field-directed 5-fluorouracil 0.5%/salicylic acid 10% in actinic keratosis.
Ulrich M; Alarcon I; Malvehy J; Puig S
Dermatology; 2015; 230(3):193-8. PubMed ID: 25721522
[TBL] [Abstract][Full Text] [Related]
45. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
Bettencourt MS
J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
[TBL] [Abstract][Full Text] [Related]
46. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
48. Use of reflectance confocal microscopy to evaluate 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III, randomized, double-blind, vehicle-controlled trial.
Ulrich M; Reinhold U; Falqués M; Rodriguez Azeredo R; Stockfleth E
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):390-396. PubMed ID: 28960520
[TBL] [Abstract][Full Text] [Related]
49. Regression Analysis of Local Skin Reactions to Predict Clearance of Actinic Keratosis on the Face in Patients Treated With Ingenol Mebutate Gel: Experience from Randomized Controlled Trials.
Jim On S; Knudsen KM; Skov T; Lebwohl M
J Drugs Dermatol; 2017 Feb; 16(2):112-114. PubMed ID: 28300852
[TBL] [Abstract][Full Text] [Related]
50. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
[TBL] [Abstract][Full Text] [Related]
51. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
Abramovits W; Oquendo M; Vincent KD; Gupta AK
Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
[No Abstract] [Full Text] [Related]
52. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.
Elías I; Ortega-Joaquín N; de la Cueva P; Del Pozo LJ; Moreno-Ramírez D; Boada A; Aguilar M; Mirada A; Mosquera E; Gibbons C; Oyagüez I
Actas Dermosifiliogr; 2016; 107(6):498-508. PubMed ID: 27130804
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
[TBL] [Abstract][Full Text] [Related]
54. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
[TBL] [Abstract][Full Text] [Related]
55. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial.
Jorizzo J; Weiss J; Furst K; VandePol C; Levy SF
Arch Dermatol; 2004 Jul; 140(7):813-6. PubMed ID: 15262691
[TBL] [Abstract][Full Text] [Related]
56. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses.
Stockfleth E; Zwingers T; Willers C
Eur J Dermatol; 2012; 22(3):370-4. PubMed ID: 22494856
[TBL] [Abstract][Full Text] [Related]
57. Indole 3-acetic acid-photodynamic therapy in the treatment of multiple actinic keratoses: A proof of concept pilot study.
Grandi V; Baldi I; Cappugi P; Mori M; Pimpinelli N
Photodiagnosis Photodyn Ther; 2016 Dec; 16():17-22. PubMed ID: 27565032
[TBL] [Abstract][Full Text] [Related]
58. Erosive pustular dermatosis of the scalp induced by ingenol mebutate.
Brambilla L; Tourlaki A; Nazzaro G
G Ital Dermatol Venereol; 2018 Oct; 153(5):743-745. PubMed ID: 28895376
[No Abstract] [Full Text] [Related]
59. Variables in Cryosurgery Technique Associated With Clearance of Actinic Keratosis.
Berman B; Shabbir AQ; MacNeil T; Knudsen KM
Dermatol Surg; 2017 Mar; 43(3):424-430. PubMed ID: 28002105
[TBL] [Abstract][Full Text] [Related]
60. Ingenol Mebutate: Expanded Utility.
Khalfe Y; Rosen T
J Drugs Dermatol; 2020 Feb 1 j; 19(2):156-161. PubMed ID: 32129959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
